Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EDP-938 (Zelicapavir) RSV Challenge Study
NCT03691623Phase 2Completed
- Sponsor
- Enanta Pharmaceuticals
- Start
- Oct 2018
- Primary completion
- Sep 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of zelicapavir in respiratory syncytial virus infection (RSV) (6 arms), sponsored by Enanta Pharmaceuticals. Primary endpoint: Area Under the Curve of Respiratory Syncytial Virus Viral Load. Started Oct 2018; status: completed.
02
Drugs
zelicapavir
03
Conditions
respiratory syncytial virus infection (RSV)
Beyond the preview
Go deeper on NCT03691623.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03691623.